Fox Chase Cancer Center News

PHILADELPHIA (December 5, 2017) — Lori J. Goldstein, MD, FASCO, Deputy Associate Director of Clinical Research,  Professor of Medical Oncology and the Director of Naomi and Phil Lippincott Breast Evaluation Center at Fox Chase Cancer Center, is one of 27 breast oncologists across the country being recognized by Forbes as an exemplary physician in the field of oncology.

PHILADELPHIA (December 1, 2017) – Fox Chase Cancer Center is raising awareness on the risk factors for lung cancer. Lung cancer is the second most common cancer in both men and women, and the leading cause of cancer death, according to the American Cancer Society (ACS), and is by far the leading cause of cancer death.

PHILADELPHIA (December 1, 2017) – HIV patients who are treated with combination anti-retroviral therapy (cART) can safely undergo chemotherapy to treat associated lymphomas at the same time, researchers from the AIDS Malignancy Consortium, including Fox Chase Cancer Center have found.

Saturday December 2nd and Thursday December 7th, 2017.

PHILADELPHIA (November 24, 2017) – Researchers at Fox Chase Cancer Center and the Johns Hopkins University School of Medicine have identified two new subtypes of laryngeal cancer, each of which indicates different survival outcomes for patients. These findings, which for the first time linked better survival to mutations damaging the genes NSD1 and NSD2, were validated in an independent cohort of patients treated at Fox Chase and Johns Hopkins.

PHILADELPHIA (November 21, 2017) — The screening will be held at American Legion Post #366, 7976 Oxford Ave, on Wednesday November 29, 2017. Doors will open at 5:30 p.m. and Fundakowski and staff will provide the screenings.

Washington DC (November 20, 2017) — Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. This year 396 members have been awarded this honor because of their scientifically or socially distinguished efforts to advance science or its applications.

PHILADELPHIA (November 9, 2017) – Although it is recommended for all colorectal cancer patients, most are not being screened for a common genetic syndrome that increases the risk of several forms of cancer and can influence treatment outcomes, according to a new study in JAMA Oncology. In the largest U.S. study of its kind, researchers at Fox Chase Cancer Center found that only 28 percent of adult colorectal cancer patients undergoing colorectal cancer resection were reported to have MMR deficiency testing performed on their tumors.